These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
525 related items for PubMed ID: 7915824
1. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. N Engl J Med; 1994 Oct 06; 331(14):904-9. PubMed ID: 7915824 [Abstract] [Full Text] [Related]
2. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study]. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Presse Med; 1995 Apr 29; 24(16):753-7. PubMed ID: 7784413 [Abstract] [Full Text] [Related]
6. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G. J Clin Endocrinol Metab; 1989 Oct 29; 69(4):725-8. PubMed ID: 2570790 [Abstract] [Full Text] [Related]
9. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine. Prescrire Int; 2000 Feb 29; 9(45):195-7. PubMed ID: 11503793 [Abstract] [Full Text] [Related]
10. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G. J Endocrinol Invest; 1994 Jan 29; 17(1):51-7. PubMed ID: 7911813 [Abstract] [Full Text] [Related]
11. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Motazedian S, Babakhani L, Fereshtehnejad SM, Mojthahedi K. Indian J Med Res; 2010 May 29; 131():670-4. PubMed ID: 20516539 [Abstract] [Full Text] [Related]
12. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A. J Clin Endocrinol Metab; 2001 Nov 29; 86(11):5256-61. PubMed ID: 11701688 [Abstract] [Full Text] [Related]
17. Dopamine agonist therapy in hyperprolactinemia. Webster J. J Reprod Med; 1999 Dec 29; 44(12 Suppl):1105-10. PubMed ID: 10649819 [Abstract] [Full Text] [Related]
18. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. N Engl J Med; 2003 Nov 20; 349(21):2023-33. PubMed ID: 14627787 [Abstract] [Full Text] [Related]
19. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J. Drug Saf; 1996 Apr 20; 14(4):228-38. PubMed ID: 8713691 [Abstract] [Full Text] [Related]
20. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Rains CP, Bryson HM, Fitton A. Drugs; 1995 Feb 20; 49(2):255-79. PubMed ID: 7729332 [Abstract] [Full Text] [Related] Page: [Next] [New Search]